ENHERTU (fam-trastuzumab deruxtecan) stands as a revolutionary milestone in cancer therapeutics, fundamentally transforming treatment approaches for HER2-positive malignancies. This groundbreaking antibody-drug conjugate, created through strategic collaboration between Daiichi Sankyo and AstraZeneca, has achieved remarkable regulatory success with approvals spanning breast cancer, gastric...
العربية
Français
Español
Português
Deutsch
Türkçe
Nederlands
Italiano
Русский
Română
Português
Ελληνικά
Tiếng Việt